All In Biotech

Drug Trial Radar · NCT06831812

Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of AV-1959R in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Jun 12, 2024

Primary completion

Dec 1, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Nuravax, Inc.Industry
Sponsor type
Industry
Collaborators
Arvax
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60. Participants will receive three intramuscular injections of either adjuvanted AV-1959R (100 µg or 300 µg) or adjuvanted placebo at Weeks 0, 4, and 14, followed by an 8-week follow-up. Researchers will monitor for side effects and measure anti-Aβ antibody levels to assess immune response. This study will help determine if AV-1959R is safe and effective in generating a targeted immune response.

Conditions

  • Alzheimer Disease
  • Alzheimer Disease (AD)
  • Alzheimers Disease Prevention

Interventions

  • AV-1959R (Abeta vaccine)Biological

    AV-1959R is an investigational adjuvanted vaccine designed to induce a targeted immune response against beta-amyloid (Aβ) to support the primary prevention of Alzheimer's disease and the treatment of asymptomatic preclinical Alzheimer's disease. It is administered intramuscularly (IM) at doses of 100 µg or 300 µg on Weeks 0, 4, and 14, in combination with the adjuvant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of AV-1959R Compared to PlaceboTime frame: Up to 26 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Arvax

    Adelaide, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.